Positive preclinical antiviral and safety profile of MIV-802 supports continued development
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announce that the preclinical antiviral and safety profile of MIV-802, Medivir’s wholly-owned nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus (HCV) infection, was presented at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL), taking place in Vienna from April 22-26. The presentation, entitled “Preclinical characterization of MIV-802, a novel uridine nucleotide HCV NS5B polymerase inhibitor, for treatment of hepatitis C virus infection”